BOSTON, July 8, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, August 8, 2024. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 8, 2024. The call can be accessed via teleconference at: Q1 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will rece ...

Core Insights - Haemonetics (HAE) has experienced significant selling pressure, resulting in a 5.2% decline over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [3]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for HAE is currently at 29.65, suggesting that the stock is in oversold territory and may be due for a rebound as selling pressure could be exhausting [5]. - RSI is a momentum oscillator that ranges from 0 to 100, with readings below 30 typically indicating that a stock is oversold [5]. Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for HAE, leading to a 0.4% increase in the consensus EPS estimate over the last 30 days [2]. - HAE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for price appreciation [2].

The latest development is expected to help Haemonetics grab opportunities in the growing vascular closure solutions space. Earlier this year, VASCADE MVP XL system gained pre-market approval from the U.S. Food and Drug Administration. VASCADE MVP XL, while including closure solutions for procedures requiring 10-12F sheaths, is anticipated to upgrade the existing range of vascular closure solutions to cater to the increasing demand for catheter-based ablation technologies. Haemonetics is confident about impr ...

Haemonetics' current VASCADE portfolio includes the VASCADE system, designed for "small-bore" femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP® system, designed for "mid-bore" multi-access femoral venous closure with 6-12F procedural sheaths. The upsized VASCADE MVP XL system utilizes 58% more collagen and a larger disc than the current VASCADE MVP system, providing a robust closure solution for procedures requiring 10-12F sheaths (up to 15F in outer diameter) ...

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. HAE currently has a forward P/E ratio of 18.83, while BSX has a forward P/E of 33.16. We also note that HAE has a PEG ratio of 1.57. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BSX currently has a PEG ratio of 2.65. Both HAE and BSX are impressiv ...

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well. Stock to Watch: Haemonetics (HAE) Haemonetics Corporation provides blood management solutions to customers encompassing blood and plasma collectors, hospitals and health care providers globally. The company's portfolio of integrated devices, information management, and consulting service ...

Haemonetics' Plasma revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024. The rollout of Persona — the company's proprietary technology proven to increase yield from 9% to 12% on average — continues to gain momentum, with more than 25 million collections. Excluding the effects of the Consolidated Screening List's ( ...

Currently, the Zacks Medical-Outpatient and Home Healthcare Industry is in the top 13% of over 250 Zacks industries with RadNet (RDNT) and U.S. Physical Therapy (USPH) being two standouts. Medical-Products Indicative of such is that Haemonetics trades at a reasonable 18.2X forward earnings multiple considering its attractive growth prospects, and in this regard, the strong performance of Lantheus could very well continue as its stock still appears to be cheap with a forward P/E of 11.4X compared to the indu ...

Here is a stock with buy rank and strong momentum characteristics for investors to consider today, June 6th: Haemonetics' shares gained 14.2% over the last three months compared with the S&P 500's advance of 3.3%. The company possesses a Momentum Score of B. Learn more about the Momentum score and how it is calculated here. Haemonetics Corporation (HAE) : This healthcare company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days ...

Howmet Aerospace Inc. (HWM) : This company that provides advanced engineered solutions for the aerospace and transportation sectors has seen the Zacks Consensus Estimate for its current year earnings increasing 9.6% over the last 60 days. Smurfit Kappa Group Plc (SMFKY) : This manufacturer of containerboard, corrugated containers, and other paper-based packaging products has seen the Zacks Consensus Estimate for its current year earnings increasing 4.8% over the last 60 days. Ligand Pharmaceuticals Incorpor ...